Michael E. Wechsler, MD, MMSc, is the director of the National Jewish Health (NJH)/Cohen Family Asthma Institute and a professor of medicine in the division of pulmonary, critical care, and sleep medicine at NJH in Denver, CO. Dr Wechsler received his bachelor and master degrees from Harvard University in Boston, MA and his medical degree from McGill University in Montreal, Canada. He completed medical training at Beth Israel Hospital in Boston, and as part of the Harvard Combined Pulmonary and Critical Care Fellowship Training Program.
Dr Wechsler’s research focuses on clinical and translational asthma with emphasis on clinical trials in asthma, novel asthma therapies, bronchial thermoplasty, asthma pharmacogenomics, and management of eosinophilic granulomatosis with polyangiitis (ie, Churg-Strauss Syndrome, CSS). He has led studies focusing on novel biologic agents for asthma and related diseases, including benralizumab, dupilumab, mepolizumab, reslizumab, and tezepelumab.
Dr Wechsler has published more than 185 peer-reviewed manuscripts relating to asthma, CSS, and eosinophilic lung diseases. He is currently an associate editor of the journal, Chest and has served as an associate editor of the journal, Allergy, and on the editorial board of the European Journal of Clinical Investigation. He was a member of the steering committee and site principal investigator of the NIH-sponsored Asthma Clinical Research Network (ACRN, now called AsthmaNet), a multicenter asthma clinical trials consortium, and currently serves as the PI of the Denver site of the Precision Intervention in Severe/Exacerbating Asthma (PRECISE) network. As a member of the American Society of Clinical Investigation, he has participated in many different task forces related to the study of eosinophilic lung diseases that were sponsored by the NIH, the FDA, the European Respiratory Society, and the International Eosinophil Society.